Metsera Inc.
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About Metsera Inc.
Metsera Inc is a clinical-stage biotechnology company developing next-generation injectable and oral nutrient-stimulated hormone (NuSH) analog peptides to treat obesity, overweight, and related conditions. The Company has developed and is implementing proprietary methods and platform technologies to advance a broad, scalable, and combinable portfolio of injectable and oral NuSH analog peptides with the potential to address not only the limitations of approved therapies but also many of the anticipated limitations of next-generation therapies in development. The Company uses its proprietary MINT peptide library of NuSH analog peptides alongside its Half-life Augmentation by Lipid Optimization half-life extending platform.
/ 
Frequently asked questions
To buy Metsera Inc. stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Metsera Inc. by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Metsera Inc. is MTSR:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Metsera Inc. has its primary listing on NASDAQ. You can trade Metsera Inc. with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Metsera Inc. is available to trade on SaxoInvestor and SaxoTraderGO. You can buy shares directly and include Metsera Inc. as part of a broader investment portfolio. Explore our SaxoInvestor platform.
Learn more about investing and trading at Saxo’s educational content hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures— so you can make more informed decisions when considering shares like Metsera Inc..